A WORLD-CLASS LINE-UP

Successful, innovative, and entrepreneurial life sciences professional, with 19+ years of progressive global business experience in new business and market development, innovation, and R&D. Proven track record of delivering new and cutting-edge products, technology platforms, and services to a large and diverse customer base from ideation to product launch and market expansion.

Howard J Federoff, MD, PhD is co-founder, director and Chief Medical Officer of Ryne Bio, an allogeneic stem cell start-up company focused on neurologic disorders. He also co-founded in 2022 Kaleibe a gene therapy focused on rare neurodegenerative diseases. He is the former CEO, President and director of Brooklyn ImmunoTherapeutics. He was receently a distinguished professor of neurology at the University of California, Irvine. He is the former CEO of UCI Health, vice chancellor for Health Affairs and dean of the UCI School of Medicine.

Jessica is the Senior Director of Clinical and Regulatory Affairs for Mydecine Innovations Group. She has spent the last ten years in the clinical research industry and has worked closely with cross-functional teams to develop clinical evidence generation strategies for global indication submissions. Jessica has supported and published research in robotics, orthopaedics, trauma, biologics, transcranial magnetic stimulation, and now psychedelic-assisted psychotherapy. She is enthusiastic about the future of integrative healing models in the United States healthcare system. Jessica received her graduate degree in Clinical Research Administration from the George Washington University and resides in the Greater Philadelphia area in the United States.

Jim Fries is a success-based executive with more than 25 years of experience building medical device and diagnostic companies across all pathways, including growth-oriented commercial initiatives, regulatory, and market access. Jim has been involved in driving thought-leader panels and committees within the areas of vascular intervention, cardiometabolics, diabetes, orthopedics, and pharmaceutical quality, which has resulted in numerous guidelines and consensus papers. Jim became CEO of Rx-360 in February of 2018, as a way of fulfilling his personal lifelong commitment to patient safety.

Josh Marsh is a member of the Advanced Drug Delivery Technologies team at Lonza’s site in Bend, Oregon, USA. He started his career at the Bend site in 2016. Josh has focused on the design of amorphous solid dispersion formulations and informative dissolution testing with the goal of improved bio-availability. He is passionate about utilizing PBPK modeling to further the understanding of in vivo drug absorption, and the design of better drug products for clients and patients. Josh earned his B.S. in Chemistry from Oregon State University.

Mr. Michailaros provides over 21 years of drug product expertise with both oral and solid processes, and product development and manufacturing. He specializes in difficult technical formulation and manufacturing challenges and products with unique requirements, including controlled release, zero-order release, abuse deterrence, pediatric formulations, oral disintegration. In addition, he has developed, and optimized products including controlled release tablets, abuse deterred capsules, pediatric formulations, solid and liquid filled capsules, suspensions, inhaled products, and transdermals. Mr. Michailaros has helped author regulatory submissions in the EU as well as in the US and has worked extensively with international vendors. He has extensive experience in project management, scale-up, tech transfer and validation, lean manufacturing, six sigma/process excellence, design of experiments (DOE), chemistry manufacturing and controls (CMC) regulatory submission authoring, capital projects and third-party manufacturing management. 

Marisa is an Award-winning communications and public relations executive with proven experience leading organization-wide, integrated internal and external communications strategy development and execution, and managing direct reports. Corporate and consultancy background, with leadership team experience. Keen intuition and ability to cultivate relationships and influence colleagues and stakeholders in highly matrixed environments. Lean Six Sigma Yellow Belt, Certified Executive/Professional Coach and Accredited in Public Relations.

Modestus Obochi (he goes by Modi) is an accomplished senior executive with over 25 years of diverse experiences growing revenues and shareholder values across biotech and pharma companies. A visionary leader, team builder, and patient-centric innovator, Modi’s collaborative leadership style and operational expertise enable individuals and teams to consistently exceed their potentials and deliver superior, sustainable results.

Modi has successfully structured and closed multiple strategic transactions worth over $5B while holding leadership positions across marketing, portfolio strategy and management, and business development, including Global Head of Strategic Marketing and Global Expansion for Hospira’s $3.5B specialty injectable pharmaceutical business; Head of Commercial Development for Pfizer’s $7B injectable portfolio and Global Vice President for Baxter’s $1B pharmaceutical business unit.

Michael Frank is the Digital Ventures Lead in Memorial Sloan Kettering’s Office of Technology Development. He is a member of the Digital Health team in OTD’s Technology Management and Commercialization group.
Before joining MSK in 2021, Michael spent more than 15 years in life sciences and digital venture roles in the biopharmaceutical and management consulting industries. Most recently, he worked at Pfizer, Inc. as Senior Director, Breakthrough Change in the CEO’s Transformation/Innovation function. Earlier, Michael worked as a strategy consultant at Booz & Co (a PWC Company) and PA Consulting. He was also VP of technology at Phosplatin Therapeutics, a NYC biotech startup, and Director of BD and Commercial Operations at CombinatoRx.

Marisa is an Award-winning communications and public relations executive with proven experience leading organization-wide, integrated internal and external communications strategy development and execution, and managing direct reports. Corporate and consultancy background, with leadership team experience. Keen intuition and ability to cultivate relationships and influence colleagues and stakeholders in highly matrixed environments. Lean Six Sigma Yellow Belt, Certified Executive/Professional Coach and Accredited in Public Relations.

Peter is the President of xCell Strategic Consulting, a consulting firm to the Pharmaceutical Industry. xCell provides consulting services in the areas of Drug Development, Outsourcing, and Supply Chain. In addition, xCell Provides advice and support for M&A in the Pharmaceutical Services Industry. Prior to founding xCell, Peter served as Division President of Qualitest, Endo Pharmaceutical’s Generic Drug Division. He also served as the President of North America Commercial Operations and CEO at Patheon Pharmaceuticals. Patheon is a leading Contract Manufacturing and Contract Research Organization which at the time was Publicly Traded and had $700 million in revenues and 5000 employees.

Prior to joining Patheon, Peter spent 14 years with Wyeth Pharmaceuticals. While at Wyeth, he oversaw a significant portion of the Manufacturing and Supply Chain organization including Consumer Products such as Advil and Centrum Vitamins, Branded Drug Products and Vaccines such as Prevnar. He also oversaw Global Engineering and expansion programs to support drug manufacturing and Research and Development. .Peter also spent 14 years at SmithKline Beecham (now GlaxoSmithKline) before joining Wyeth. His assignments included significant international project work in Europe and Asia and operations experience with injectable product manufacturing.

Peter is a member of the Global Pharmaceutical Manufacturing Leadership Forum of the ISPE and is a frequent speaker at Industry events. He serves on the Board of Abzena, a Biopharmaceutical Company and as the Chairman of the Board of Trustees of the Pharma, Biopharma Outsourcing Association (PBOA); a non-profit trade association that represents the needs and interests of Pharmaceutical Contract Development & Manufacturing Organizations (CDMOs).

Peter previously served on the Board of IPS – a Global Healthcare Engineering Company, the Board of Frontida Laboratories and the Board of CASA Youth Services – a non-profit organization serving the needs of Children in the Foster Care environment. He has a BS in Mechanical Engineering from Villanova University and an MBA from Philadelphia University. Peter and his wife Lynn reside in Valley Forge, Pennsylvania.

Mr. Peter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a member of Pfizer’s Global Manufacturing Leadership Team with responsibilities for global procurement, global external supply and a portfolio of Pfizer internal manufacturing sites in North America, Europe and Asia.

Later, he served as General Manager of Pfizer’s contract manufacturing business and as Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and currently serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.

Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese including a 3-year expatriate assignment in France.

He holds a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania

Rick L. Knight is the Global Head Strategic Account Management at Pfizer CentreOne. Rick is a high-impact healthcare executive with extensive experience in global pharmaceutical and medical device businesses. Rick began his career in sales and marketing and has held leadership roles at AmerisourceBergen, Honeywell, and Becton Dickinson.

Prior to joining Pfizer CentreOne Rick was Vice President and General Manager at Cardinal Health where he grew a suite of 3-businesses into one of the largest suppliers of multi-source prescription and over-the-counter products in the industry, with a portfolio spanning nearly 50 therapeutic categories.

He has also led patient care efforts as a Director of Hospital Pharmacy and Supervising Retail Pharmacist.

Rick holds an undergraduate degree from Albany College of Pharmacy and Health Sciences and an MBA from the University of Rochester’s Simon Business School.

Rick is a technical operation professional, driven to develop and lead high-performing organizations and committed to the success of my teams and my colleagues. Rick is strongly committed to collaborating acrossfunctional lines and drive a vision for success. His diverse background and experience has enabled him to play a leading role in all aspects of the External Supply site and its development to its current state, as well as creating the vision for the future.

Sheila currently is an Executive Director of Global Supply Planning & Transformation at Amgen. She has a long career in the pharmaceutical and industrial manufacturing companies in supply chain and has worked for companies like GSK, Honeywell, Merck and BMS in roles of increasing responsibility. Her experience spans Information Technology, Supply Planning, Product and Network Strategy and finally End to End SC transformation.